1087 related articles for article (PubMed ID: 35245942)
1. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
Saravolatz LD; Depcinski S; Sharma M
Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
[TBL] [Abstract][Full Text] [Related]
2. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
3. Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.
Sutanto ST; Sinto R; Pasaribu A; Shakinah S
Acta Med Indones; 2022 Oct; 54(4):638-644. PubMed ID: 36624705
[TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
[TBL] [Abstract][Full Text] [Related]
6. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
Atmar RL; Finch N
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
Gentry CA; Nguyen P; Thind SK; Kurdgelashvili G; Williams RJ
J Infect; 2023 Mar; 86(3):248-255. PubMed ID: 36702309
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Mutalik P; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
Ann Intern Med; 2023 Jun; 176(6):807-816. PubMed ID: 37276589
[TBL] [Abstract][Full Text] [Related]
9. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
[No Abstract] [Full Text] [Related]
10. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the use of Paxlovid in clinical practice.
McCarthy MW
Drugs Today (Barc); 2022 Nov; 58(11):539-546. PubMed ID: 36422515
[TBL] [Abstract][Full Text] [Related]
12. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry.
Salmanton-García J; Marchesi F; Koehler P; Weinbergerová B; Čolović N; Falces-Romero I; Buquicchio C; Farina F; van Praet J; Biernat MM; Itri F; Prezioso L; Tascini C; Vena A; Romano A; Delia M; Dávila-Valls J; Martín-Pérez S; Lavilla-Rubira E; Adžić-Vukičević T; García-Bordallo D; López-García A; Criscuolo M; Petzer V; Fracchiolla NS; Espigado I; Sili U; Meers S; Erben N; Cattaneo C; Tragiannidis A; Gavriilaki E; Schönlein M; Mitrovic M; Pantic N; Merelli M; Labrador J; Hernández-Rivas JÁ; Glenthøj A; Fouquet G; Del Principe MI; Dargenio M; Calbacho M; Besson C; Kohn M; Gräfe S; Hersby DS; Arellano E; Çolak GM; Wolf D; Marchetti M; Nordlander A; Blennow O; Cordoba R; Mišković B; Mladenović M; Bavastro M; Limongelli A; Rahimli L; Pagano L; Cornely OA
Int J Antimicrob Agents; 2023 Oct; 62(4):106952. PubMed ID: 37582478
[TBL] [Abstract][Full Text] [Related]
13. Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models.
Cox RM; Lieber CM; Wolf JD; Karimi A; Lieberman NAP; Sticher ZM; Roychoudhury P; Andrews MK; Krueger RE; Natchus MG; Painter GR; Kolykhalov AA; Greninger AL; Plemper RK
Nat Commun; 2023 Aug; 14(1):4731. PubMed ID: 37550333
[TBL] [Abstract][Full Text] [Related]
14. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
[TBL] [Abstract][Full Text] [Related]
15. Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study.
Spiliopoulou V; Ntanasis-Stathopoulos I; Malandrakis P; Gavriatopoulou M; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Eleutherakis-Papaiakovou E; Kastritis E; Dimopoulos MA; Terpos E
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992413
[TBL] [Abstract][Full Text] [Related]
16. First-generation oral antivirals against SARS-CoV-2.
Sendi P; Razonable RR; Nelson SB; Soriano A; Gandhi RT
Clin Microbiol Infect; 2022 Sep; 28(9):1230-1235. PubMed ID: 35545195
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes.
Ma BH; Yip TC; Lui GC; Lai MS; Hui E; Wong VW; Tse YK; Chan HL; Hui DS; Kwok TC; Wong GL
JAMA Netw Open; 2023 Apr; 6(4):e2310887. PubMed ID: 37103932
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between M
Dawood AA
Adv Med Sci; 2023 Mar; 68(1):1-9. PubMed ID: 36368287
[TBL] [Abstract][Full Text] [Related]
19. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: A systematic review and meta-analysis.
Amani B; Akbarzadeh A; Amani B; Shabestan R; Khorramnia S; Navidi Z; Rajabkhah K; Kardanmoghadam V
J Med Virol; 2023 Jun; 95(6):e28889. PubMed ID: 37368841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]